US Stem Cell (USRM) Stock Price

US Stem Cell Price

OTC·CLOSED
0.00
​
Market closed

Revenue has compounded at 2.6% per year over the past 19 years to 82,100.00 USD. US Stem Cell's net margin stands at -3,481.0%, down from -32.2% several years earlier.

US Stem Cell stock price

Access this data via the Eulerpool API

US Stem Cell business model & stock analysis

US Stem Cell Inc is a company specializing in the field of regenerative medicine. It was founded in 1999 and is headquartered in Sunrise, Florida. The company has experienced rapid development in recent years and is one of the leading providers of stem cell therapies in the USA. The business model of US Stem Cell is based on the development and marketing of stem cell products and therapies that are intended to help patients improve their health and treat diseases. The company focuses on a range of therapeutic applications, such as the treatment of degenerative diseases, injuries, and chronic pain. US Stem Cell operates several divisions, including the Cell Processing and Storage Center, which specializes in the processing and storage of stem cells. The company also has its own research and development team that develops products and therapies and subjects them to clinical trials. US Stem Cell offers various products and therapies, including autologous stem cell therapy. In this treatment, stem cells are taken from the patient's own body, processed, and then used at the affected site. This is intended to aid in the regeneration of damaged tissue and reduce inflammation in the body. Another treatment method is the use of exogenous stem cells sourced from other donors. US Stem Cell has also entered into a partnership with the Advanced Regenerative Manufacturing Institute (ARMI) to research and develop technology for the production of biological materials and tissues. This collaboration aims to increase the availability of stem cell therapies and advance research in this field. US Stem Cell has experienced some controversies in recent years, particularly related to the use of inappropriate protocols and the performance of stem cell therapies without sufficient scientific evidence. However, the company has emphasized that their therapies are based on scientific knowledge and rigorous protocols, and that they work closely with medical professionals to ensure the safety and efficacy of their treatments. Overall, US Stem Cell Inc has established itself as a significant player in the field of regenerative medicine, particularly in the area of stem cell therapy. The company is committed to developing new therapies that help patients improve their quality of life and treat diseases. Despite some controversies, US Stem Cell remains an important and promising company in the biotechnology industry.

Frequently asked questions about US Stem Cell

The business model of US Stem Cell Inc is centered around the development and commercialization of innovative cell therapy products and services. As a biotechnology company, US Stem Cell Inc focuses on advancing regenerative medicine to provide potential treatments for various medical conditions. Their approach involves extracting stem cells from the patient's own adipose tissue, which are then processed to develop personalized treatment options. By leveraging their proprietary technology and expertise, US Stem Cell Inc aims to offer therapeutic solutions for individuals seeking alternative and potentially more effective medical treatments.

US Stem Cell Inc is primarily active in the field of regenerative medicine. This innovative company utilizes cutting-edge stem cell technologies to develop and provide advanced personalized cell therapies. They focus on creating effective treatments and potential cures for various medical conditions. With their expertise in stem cell research and development, US Stem Cell Inc aims to revolutionize the healthcare industry, offering solutions that promote natural healing and improved quality of life for patients.

The main competitors of US Stem Cell Inc in the market include companies like Mesoblast Limited, Novartis International AG, Celgene Corporation, and Vericel Corporation.

US Stem Cell Inc, founded in 1999, is a leading biotechnology company in the United States. It specializes in the research and development of innovative cell-based therapies and regenerative medicine solutions. The company focuses on the development of unique and proprietary methods to isolate and culture stem cells derived from adipose tissue, known as ADRCs (Adipose-Derived Regenerative Cells). With a strong commitment to advancing medical treatments, US Stem Cell Inc has proven itself as a pioneer in the field of regenerative medicine. Through clinical trials and collaborations, the company strives to provide novel therapies for various medical conditions and improve patients' quality of life.

US Stem Cell Inc has achieved several significant milestones. One notable accomplishment is the development and commercialization of their proprietary cell therapy products. The company has also made advancements in the field of regenerative medicine, conducting clinical trials to assess the safety and efficacy of their innovative therapies. Furthermore, US Stem Cell Inc has established partnerships and collaborations with renowned medical institutions and research organizations, contributing to the advancement of stem cell research and therapy. These milestones solidify US Stem Cell Inc's position as a leading player in the industry, showcasing their dedication to advancing the field of regenerative medicine.

US Stem Cell Inc primarily operates in the United States, where it has its headquarters and numerous clinics. The company focuses on providing innovative and advanced regenerative medicine treatments and stem cell therapies within various regions of the United States. With its commitment to advancing the field of regenerative medicine, US Stem Cell Inc aims to revolutionize healthcare and provide hope to patients seeking improved quality of life.

US Stem Cell Inc represents a commitment to advancing regenerative medicine through innovative therapies. The company's corporate philosophy revolves around providing patients with groundbreaking treatments using their own cells. US Stem Cell Inc values patient safety, efficacy, and personalized care. With a focus on developing and commercializing stem cell-based therapies, they strive to improve the quality of life for individuals suffering from various diseases and conditions. As a leader in the field, US Stem Cell Inc is dedicated to delivering cutting-edge solutions and driving advancements in regenerative medicine.

Converted at the current exchange rate, the US Stem Cell share trades at 0.00 EUR (0.00 USD).

US Stem Cell Inc is a biotechnology company specializing in the development of unique and advanced regenerative treatments and products based on stem cells. The company is headquartered in Sunrise, Florida and was founded in 1999. US Stem Cell's business model is focused on meeting the growing demand for effective alternatives to conventional medical treatment of diseases and injuries. One important division of US Stem Cell is clinical research. The company has an extensive research department specializing in the development of innovative stem cell treatments. The goal of this work is to advance the application of stem cells for tissue regeneration and disease treatment. US Stem Cell has conducted a number of clinical trials and is currently in the phase of clinical testing for several procedures and technologies. Additionally, the company collaborates closely with renowned institutions and universities to make new discoveries in the field of stem cell research. Another important division of US Stem Cell is the manufacturing and marketing of stem cell products. The company offers various products based on the use of stem cells. These products are used to promote tissue regeneration, support the immune system, rejuvenate the skin, and provide many other benefits. The company has developed a variety of stem cell products, including Hylasome, Lipotight, Skinfinity, and many others. US Stem Cell also operates several medical clinics. These clinics are focused on offering high-quality and effective stem cell treatments. The clinics are equipped with state-of-the-art technology and facilities and offer a variety of treatments, including injections of autologous bone marrow stem cells (AMSCs), stem cell procedures to support tissue regeneration, and other stem cell treatments to support the immune system. In recent years, US Stem Cell has experienced a strong growth phase. The company has successfully filed 300 patents since its inception and employs several accredited physicians in research and treatment. The company employs several hundred employees and operates facilities in multiple countries. Thanks to its continuous investments and efforts to promote scientific research that allows for innovations in the use of stem cells, US Stem Cell Inc remains committed to its goal of offering the best products and treatments in the field of regenerative medicine. Ultimately, the goal of US Stem Cell is to contribute to the market of stem cell production and regenerative medicine through outstanding innovations, products, and services. The company is constantly striving to promote the health and well-being of its patients by utilizing the latest technologies, products, and procedures and successfully integrating the application of stem cells into medical practice.

The revenue cannot currently be calculated for US Stem Cell.

The profit cannot currently be calculated for US Stem Cell.

The P/E ratio cannot be calculated for US Stem Cell at the moment.

The P/S cannot be calculated for US Stem Cell currently.

The Eulerpool Quality Score for US Stem Cell is 2/10.

The ISIN of US Stem Cell is US90350U1007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of US Stem Cell is A14X6B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of US Stem Cell is USRM. The ticker symbol is used to trade US Stem Cell shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
27,366.67 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 19, 2008
ISIN
US90350U1007
Cusip
90350U100
Sedol
BYM2LC0
Market capitalization
59,155.83 USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
49.29 %
Gross Margin
71.01 %
EBIT Margin
-2,095.62 %
Net Margin
-3,481.00 %
EPS (Earnings Per Share)
-0.00 USD
Net Debt / EBIT
-5.20
Debt/Equity
-0.61
Last updated Oct 5, 2026, 12:58 PM

US Stem Cell Ticker

OTC · USRMOTC · USRM

US Stem Cell FIGI

USRM:US · BBG000R0ZM84USRM:PQ · BBG000R0ZSB7USRM:UV · BBG000R0ZT52USRMUSD:EO · BBG00KFLVM90USRMUSD:XH · BBG00KFLVMD5USRMUSD:XF · BBG00KFLVMG2USRMUSD:XE · BBG00KFLVMJ9USRMUSD:XJ · BBG00KFLVMK7USRMUSD:XL · BBG00KFLVML6USRMUSD:XG · BBG00KFLVMM5USRMUSD:XO · BBG00KFLVMN4USRMUSD:XS · BBG00KFLVMS9

All fundamentals and in-depth analysis of US Stem Cell

Our stock analysis for US Stem Cell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of US Stem Cell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.